Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: Costecat Study

Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: Costecat Study

Background: Patients with lung cancer (LC) are at significantly higher risk of developing venous thromboembolism (VTE), which may lead to increased use of health resources and the cost of management. The main aim of the study was to determine the cost of the management of VTE events in patients with...

Full description

Bibliographic Details
Main Authors: Ana Rosa Rubio-Salvador, Vicente Escudero-Vilaplana, José Antonio Marcos Rodríguez, Irene Mangues-Bafalluy, Beatriz Bernárdez Ferrán, Carlos García Collado, Roberto Collado-Borrell, María Dolores Alvarado Fernández, José Ignacio Chacón López-Muñiz, María Yébenes Cortés, Manuel Gómez Barrera, Miguel Ángel Calleja-Hernández
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:International Journal of Environmental Research and Public Health
Subjects:
cancer
thromboembolic disease
LMWH
cost
economic impact
Online Access:https://www.mdpi.com/1660-4601/18/2/394

Similar Items

Similar Items